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Pharmacotherapeutic aspects 
of dementia care in Malta
Abstract
Dementia is the most common neurodegenerative disorder 
of old age affecting one percent of the local general population. 
It is a major predictor of morbidity and mortality in the elderly, 
adding a significant burden on health and social care systems 
across Europe. The financial impact of caring for individuals 
with dementia is considerable and progressive loss of cognitive 
function does not only pose challenges to the patients but 
also adds significant strain on the well-being of caregivers 
and family members. Although no cure is available, disease 
progression can be delayed by early intervention and by the 
use of pharmacotherapeutic agents that interfere with central 
neurotransmitter systems involved in cognitive processes. 
This review presents current trends in pharmacotherapeutic 
intervention in dementia care together with caregiver 
perceptions on treatment expectations in Malta.   
Charles Scerri, Stephen Abela, Anthea Innes
Introduction
Dementia is a complex clinical syndrome associated with 
behavioural, cognitive and personality changes. It usually 
presents itself as impairment in memory, abstract thinking, 
impaired judgment and other disturbances that are of such 
severity that they interfere with work and social activities.1 
Several diseases are known to cause dementia. Alzheimer’s 
disease (AD) accounts for 50-70% of cases followed by Vascular 
dementia, Lewy Body Disease, fronto-temporal dementia and 
dementia secondary to disease.2 According to an estimate from 
World Health Organization (WHO), dementia is responsible for 
more years lived with disability in people older than 60 years 
(11.2%) than stroke (9.5%), cardiovascular disease (5%) or all 
forms of cancer (2.4%).3 Currently, there are more than 7.3 
million people with dementia in Europe, a figure that is expected 
to double by the next 30 years.4 This will result in a growing 
burden on health care resources and family members who, in 
the majority of cases, provide informal care at home. A recent 
study estimated that approximately one percent of the general 
population in Malta has dementia, a figure that is expected to 
increase significantly by the year 2050 (Table 1).5
Over the last two decades, a number of therapeutic strategies 
have been developed for the symptomatic management of 
the most common forms of dementia, particularly AD. The 
latter is characterised by the presence of amyloid plaques and 
neurofibrillary tangles coupled with significant degeneration of the 
central cholinergic system resulting in cognitive decline.6 Indeed, 
the first pharmacological agents to be approved for symptomatic 
treatment of AD were the acetylcholinesterase inhibitors which 
mainly block the enzyme acetylcholinesterase thus increasing 
the concentrations of the neurotransmitter acetylcholine in the 
synaptic area (Table 3). Studies showed that the use of these drugs 
(namely donepezil, galantamine and rivastigmine) significantly 
improved cognition and activities of daily living.7 Another drug 
that is also available in the therapeutic management of AD is 
the glutamatergic-system modifier memantine which partially 
blocks glutamate-induced overstimulation of the N-methyl-
D-aspartate (NMDA) receptor thus reducing calcium-induced 
cytotoxicity (Table 3). In randomised clinical trials, this drug 
demonstrated the ability to delay cognitive and functional decline 
without any significant incidence of side effects.8,9 According to the 
latest guidelines issued by the UK National Institute for Clinical 
Excellence (NICE), acetylcholinesterase inhibitors should be 
recommended for use in moderate AD whereas memantine should 
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Table 1: Current and projected number of total dementia cases in the Maltese islands (adapted from Abela et al).5
Year 30-59 60-64 65-69 70-74 75+ Total cases % of total 
population
2010 203 293 316 629 2947 4388 1.12
2015 204 268 444 749 3227 4892 1.25
2020 201 285 404 1035 3660 5585 1.44
2025 201 253 422 931 4538 6345 1.66
2035 190 257 332 881 5161 6821 1.91
2050 150 268 414 970 4567 6369 2
only be considered for clinical trials.10 Apart from Malta and Latvia, 
all EU-member states offer some form of financial reimbursement 
to any of these classes of anti-dementia drugs.
In recent years, strategies on dementia care have also been 
developed in parallel with pharmacotherapeutic research since 
caregivers suffer from high rates of physical and mental disorders 
including anxiety and depression.11 Caregivers are also generally 
excluded in providing their views on the effectiveness of anti-
dementia pharmacotherapy in ameliorating the symptoms as 
most research is focused on the disease model. A recent review 
study found that not one of the 63 papers (listed in medical 
databases) reporting on the effectiveness of drug treatments 
included the carer perspective.12 Indeed, the carer perspective 
becomes important in assessing the effectiveness of a particular 
anti-dementia pharmacotherapeutic regimen in enhancing 
the quality of life and assessing caregiver burden.13 The input 
of carers would also be instrumental in providing qualitative 
information that should aid medical professionals to adjust 
therapy ensuring better pharmacotherapeutic outcomes.
Hospital-based pharmacotherapeutic 
management
In Malta, no research has yet been carried out on the use of 
pharmacotherapeutic agents in treating the various symptoms 
observed in dementia. In order to have an indication on the use of 
anti-dementia drugs in a local hospital-based clinic, a small scale 
exercise involving ten persons with dementia was conducted 
in October 2008. Also involved were seventeen caregivers, 
the latter comprising five spouse carers (two husbands and 
three wives), nine children (eight daughters and one son) and 
three daughter-in-laws. The sample of potential caregivers was 
selected from the Zammit Clapp Hospital Memory Clinic and 
was subsequently interviewed by a member of the research 
team. All participants had to be caring for a relative who had a 
formal diagnosis of dementia, who was attending the Memory 
Clinic, who continued to live in the community and who was 
over 65 years of age. The medical history of individuals with 
dementia was analysed for parameters including Mini Mental 
Scale Examination (MMSE) scores (which classify dementia 
into mild, moderate and severe), date of first attendance to 
the Memory Clinic, date of diagnosis, medical conditions 
besides dementia and pharmacotherapy. Ethical approval was 
obtained from three sources prior to conducting the interviews 
with caregivers. These included the University of Stirling (UK) 
Ethics Committee, the University of Malta Research Ethics 
Committee and the Malta Health Department. All relatives 
participating in the study received a written information sheet 
prior to consenting to participate and this was also discussed 
verbally prior to obtaining written consent.
The results showed that more than half of the persons with 
dementia participating in the exercise had the moderate form 
of dementia in which there is clear impairment of cognitive 
function that may require continuous supervision (Figure 1). The 
rest of the patients had mild or questionably significant deficits in 
which the person with dementia continues to function normally 
with support and assistance. No patient had a Mini Mental 
State Examination score of less than 10 denoting the severe 
form of the condition which requires continuous supervision 
and assistance in their Activities of Daily Living (ADL). Table 2 
shows the time intervals from when the person with dementia 
visited the Memory Clinic for the first time until diagnosis of 
dementia and initiation of treatment was performed. The mean 
number of days elapsed from first visit to diagnosis was that of 
41.3±19.3 (mean±SEM) days. The majority of patients had their 
diagnosis of dementia during their first visit to the clinic. The 
mean number of days elapsed from diagnosis till the initiation 
of treatment was that of 69.4±42.3 (mean±SEM) days with 
most patients prescribed anti-dementia medication on the day 
of diagnosis. The mean total number of elapsed days from the 
patient first visit to the clinic till the initiation of treatment was 
of 108.3±34.9 (mean±SEM) days. Figure 2 shows the percentage 
of other pathological disorders in conjunction with dementia 
(taken as 100% to signify that all patients participating in this 
exercise had dementia). Most of the patients had depression 
and a significant number had diabetes, hypertension and 
hypecholesterolaemia. Other less common comorbidities 
included gout, anxiety, hearing loss and previous surgical 
interventions prior to dementia diagnosis. Figure 3a shows the 
amount of drugs prescribed for every person with dementia. The 
total number of drugs prescribed was 59 giving an average of 
5.9 drugs per patient. The majority of patients were prescribed 
four or more drugs. All persons with dementia, except one, 
8 Malta Medical Journal    Volume 22   Issue 03   2010
were prescribed anti-dementia pharmacotherapy which mainly 
consisted of the acetylcholinesterase inhibitor galantamine 
and the partial NMDA receptor antagonist memantine. A total 
of fifty drugs were used to control other coexisting medical 
conditions with the majority being cardiovascular agents 
followed by antidiabetics, antidepressants and lipid lowering 
agents. Supplements and vitamins were prescribed in a number 
of cases whereas antipsychotics were used in one of the patients 
(Figure 3b).
The qualitative interviews with seventeen caregivers showed 
a lack of perceived support by carers when caring for a person 
with dementia. The majority of participants mentioned the lack 
of professional healthcare services specifically aimed for patients 
with cognitive difficulties. Most importantly, caregivers reported 
the significant financial costs involved in the purchase of anti-
dementia medication since dementia is not included among the 
conditions listed in the Fifth Schedule of the Malta Social Security 
Act. It was also observed that relatives are ambivalent as to the 
effectiveness of these drugs but they were unwilling to discontinue 
treatment in case it made caregiving more difficult or that the 
symptoms will worsen. This is reported in detail elsewhere.14
Discussion
Dementia is an ever-growing condition that is associated 
with significant social, physical, psychological and psychiatric 
disability not only in individuals diagnosed with the illness 
but also in caregivers and family members. Up until recently, 
there was no effective pharmacotherapeutic intervention to 
manage the cognitive symptoms associated with dementia.10 
Although the benefits of current treatments are deemed to be 
modest in that they do not halt the disease progression, they 
represent a major step forward in the clinical management of 
these patients.12 Although the presented small scale exercise 
Table 2: Time intervals from first visit to initial diagnosis and treatment for each person with dementia (PWD) 
participating in the exercise (* signifies diagnosis of dementia during the first visit at the Memory Clinic, ** signifies 
initiation of treatment on the same day of dementia diagnosis).
PWD Days elapsed from first 
visit to diagnosis
Days elapsed from 
diagnosis to initiation 
of treatment
Total number of days 
from first visit to 
initiation of treatment
1 111 0** 111
2 n/a n/a n/a
3 0* 306 306
4 90 0** 90
5 26 0** 26
6 0* 77 77
7 0* 103 103
8 0* n/a n/a
9 145 0** 145
10 0* n/a n/a
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Figure 1: Minimental State Examination 
(MMSE) scores for each person with dementia 
(PWD) participating in the exercise together with 
interpretation of the scores according to Folstein et al.29
Score Degree of 
impairment
Day-to-day functioning
25 to 30 Questionably 
significant
May have clinically 
significant but mild deficits. 
Likely to affect only most 
demanding activities of daily 
living
20 to 25 Mild Significant effect. May 
require some supervision, 
support and assistance
10 to 20 Moderate Clear impairment. May 
require 24-hour supervision
0 to 10 Severe Marked impairment. 
Likely to require 24-hour 
supervision and assistance 
with ADL
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has its limitations in terms of the number of subjects involved, 
the general trend observed indicate that at the Zammit Clapp 
Hospital Memory Clinic, patients are mostly diagnosed early 
upon their first clinical appointment, are mostly managed with 
acetylcholinesterase inhibitors and usually suffer from other 
comorbities which may or may not be related to dementia. 
Furthermore, the overall feeling of caregivers and family 
members is that they are being left out from decisions on 
pharmacotherapy prescribed for patients with dementia under 
their care.
Various studies suggest that pharmacotherapeutic 
intervention with anti-dementia medication early in the disease 
process may slow down the disease progression and thus 
improve the quality of life for both patient and caregivers.15 
Although this exercise did not examine the time lapse prior 
to seeking clinical advice following the emergence of the first 
symptoms, it is clear that most of the patients did not seek 
medical intervention early and thus the majority were in the 
moderate stages of the disease. Reasons for such delay may 
include caregiver’s lack of knowledge or reluctance to seek 
help, and patient, family, and physician-related factors.16 In 
participating patients, pharmacotherapeutic dementia-related 
intervention consisted of the use of both acetylcholinesterase 
inhibitors and glutamatergic-system modifiers. Whether the use 
of these agents had any significant effect on delaying the disease 
progression or controlling the behavioural symptoms of our 
patients is unclear and was beyond the scope of this exercise.
Acetylcholinesterase inhibitors were the first pharmacological 
treatment approved for symptomatic treatment of AD. These 
drugs have been found to stabilise the cognitive decline for up 
to 3-6 months.17,18 Memantine, the only glutamatergic system 
modifier approved for the treatment of AD, was also reported 
to improve dementia symptoms by reducing the rate of clinical 
deterioration among patients with moderate to severe AD.9,19 
Currently there is a strong debate on the cost effectiveness of the 
Table 3. Characteristics of pharmacotherapeutic agents used in the management of Alzheimer’s disease (AChEI: 
acetylcholinesterase inhibitor, AD: Alzheimer’s disease, nAChRs: nicotinic acetylcholine receptors, NMDA: 
N-methyl-D-aspartate).28
Medication
Pharmacological 
class
Mode of action Recommended use
Potential  
adverse effects
Donepezil 
hydrochloride 
(Aricept®)
AChEI
Block 
acetylcholinesterase 
enzyme
Mild-to-moderate AD
Anorexia, diarrhoea, 
dreams, fatigue, 
insomnia, muscle 
cramps, nausea, 
vomiting, weight loss
Rivastigmine 
tartrate (Exelon®)
AChEI
Block both acetyl- 
and butyryl- 
cholinesterase 
enzymes
Mild-to-moderate AD
Anorexia, diarrhoea, 
nausea, vomiting, 
weight loss
Galantamine 
hydrobromide 
(Reminyl®)
AChEI
Block 
acetylcholinesterase 
enzyme. Allosterically 
stimulates nAChRs 
Mild-t0-moderate AD
Anorexia, nausea, 
vomiting, weight loss
Memantine 
hydrochloride 
(Axura®, Ebixa®)
Glutamatergic system 
modifier
Partial NMDA 
receptor antagonist
Moderate-to-severe 
AD
Agitation, 
constipation, 
dizziness, 
hallucinations, 
headache, insomnia
Dementia
Depression
Diabetes
Hypertension
Hyper-
cholesterolaemia
Percentage of PWD
0 20 40 60 80 100
Figure 2: Most common comorbid disorders in PWD 
participating in the exercise.
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This prescribing behaviour is in concordance with current 
recommendations denoting that early initiation of therapy is 
associated with greater long-term benefits.20 
A significant number of participating patients were 
diagnosed with depressive illness possibly indicating a high 
prevalence rate of depression in patients with dementia. This 
was also reflected by the significant use of antidepressants as part 
of the overall prescribed treatment regimen. Epidemiological 
studies show a possible pathological association between the 
two conditions, with depression possibly acting as a prodromal 
sign or early symptom of AD.21 Due to the limited number 
of patients participating in this exercise, it was not possible 
to investigate any link between depression and dementia 
although this would be an interesting research area for future 
consideration. The same is also valid with the other main 
pathologies observed. Although cardiovascular disease, diabetes 
and hypercholesterolaemia are risk factors in vascular dementia, 
these conditions are also prevalent in old age. 
The use of multiple medication (polypharmacy) in the 
elderly has always been regarded as a complex issue in 
pharmaco-geriatric management. Although polypharmacy may 
be the only choice in some individuals, multiple medication use 
may increase the risk of non-compliance, medication error and 
potentially adverse drug interactions.22 Prescribing for elderly 
patients with dementia proves to be even more challenging 
due to the changing needs that accompany cognitive decline 
and related behavioural symptoms.23 Furthermore, more 
medications may be indicated in patients with dementia due to 
the presence of other pathologies which are common in old age.24 
Our data indicated that, on average, each person with dementia 
was prescribed with more than five different medications for the 
management of dementia and other comorbidities. This finding 
raises important clinical concerns, especially for individuals 
who still live in the community, in some cases on their own. 
Furthermore, because the use of polypharmacy increases the 
risk of falls, prescribing unnecessary medication may further 
enhance institutionalisation. Polypharmacy is also associated 
with increased risk of adverse drug-drug interactions which can 
have potential life-threatening consequences in older adults. 
This is especially critical in patients with dementia who are 
cognitively impaired and therefore not be able to explain or self 
report the symptoms. Interestingly, only one drug (lorazepam) 
was found to be part of the Beers Criteria,25 a list of medications 
that are generally considered to be inappropriate when given to 
the elderly. No potentially serious drug-drug interactions were 
observed. In line with guidelines issued by NICE,10 prescription 
of antipsychotic drugs was only present in one participating 
patient attending the Memory Clinic. Recent data shows that 
the use of these drugs in persons with dementia is associated 
with an increase in the risk of fatality.26
Studies including the views and experiences of caregivers 
on the effectiveness of anti-dementia drugs are lacking with a 
major focus directed towards conventional scientific evidence 
which is mostly relevant to clinicians and research scientists. 
Figure 3: Number of PWD on polypharmacy (a) and 
total number of drugs prescribed to all patients as per 
drug mode of action or therapeutic class (b).
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widespread use of these drugs for the various stages of AD. The 
National Institute of Clinical Excellence (NICE) recommends the 
use of acetylcholinesterase inhibitors in the moderate stages of 
the disease with the use of memantine reserved only for clinical 
trials.10 This decision was widely criticised by the Royal College 
of Psychiatrists, the British Geriatric Society and the Royal 
College of Nursing as well as by various EU-based dementia 
societies. In Malta, no such recommendations exist and both 
classes of drugs can be prescribed by general practioners and 
specialists.  Interestingly, the trend observed indicated that half 
of the participating patients were recommended with the use 
of anti-dementia drugs upon diagnosis during their first visit at 
the Memory Clinic, irrespective of the severity of the condition. 
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This lack of caregiver perspective was apparent in our qualitative 
assessment of the participating subjects. Caregivers were mostly 
concerned with the lack of support from the central health 
authorities in caring for their relatives. The greatest concern 
is the lack of financial assistance in purchasing anti-dementia 
medication which, in some cases, can take up a third of the 
person with dementia pension. Together with Latvia, Malta is 
the only country where the health authorities do not offer any 
form of financial support in accessing these drugs.27 Even though 
some caregivers interviewed were unsure of the efficacy of anti-
dementia medication in slowing the disease progression, they 
were unwilling to stop treatment.
Conclusion
Although more research is needed, using a larger sample 
number, the trends observed highlight the need for a 
nationwide strategy that includes the various aspects involved 
in pharmacological and non-pharmacological management 
of dementia. Such strategy should include the views of policy 
makers, healthcare professionals as well as patients and their 
caregivers with the aim of designing and implementing a series 
of recommendations that that should enhance high-quality 
dementia care in Malta.
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